CrushSCI.com
Journal Selection & Manuscript Polishing Services
Molecular Cancer journal cover Medicine
Back to journal directory

Review Cycle Records

Molecular Cancer

Springer SCIE OA
2026 Emerging Zone 12025 CAS Zone 1 TOP2025 JCR Q1
102.8Average days
94Median days
36Fastest days
202Longest days
3322025 publications

Paper Review Records

All Paper Review Records

10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

64 days

Advances in improving cancer immunotherapy with nanotechnology: from smart nanoparticles to synergistic combination strategies

AuthorsUntack Cho; Jingjing Pu; Amit Sharma; Junhyuk Song; Ji Hyeon You; Yona Kim; Pyung Won Im; Hyung Woo Park; Hyo Eun Moon; Ho Sung Myeong; Hye Ran Park; Jian Hou; Ingo G. H. Schmidt-Wolf; Sun Ha Paek

Affiliations1. Department of Neurosurgery, Cancer Research Institute and Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine, Seoul, Korea; 2. Department of Life and Chemical Engineering, Gyeonggi University of Science and Technology, Siheung, Korea; 3. Department of Hematology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 4. Department of Integrated Oncology, Center for Integrated Oncology (CIO) Bonn, University Hospital Bonn, Bonn, Germany; 5. Department of Neurosurgery, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea; 6. Advanced Institute of Convergence Technology, Seoul National University, Suwon, Korea

Source PDF DOI Publisher page
93 days

Mutation-specific dynamics of dedifferentiation trajectories and tumor–stromal interactions in thyroid cancer

AuthorsEun Hye Joo; Young Shin Song; Han Sai Lee; Gyeongseo Jung; Eun-jae Chung; Su-jin Kim; Yoo Hyung Kim; Sun Wook Cho; Hongyoon Choi; Jae-kyung Won; Woong-Yang Park; Young Joo Park

Affiliations1. Genomic Medicine Institute Medical Research Center, Seoul National University College of Medicine, Seoul, Republic of Korea; 2. Department of Health Sciences and Technology, Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University, Seoul, Republic of Korea; 3. Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea; 4. Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea; 5. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; 6. Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, Republic of Korea; 7. Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea; 8. Department of Surgery, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea; 9. Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; 10. Department of Pathology, Seoul National University Hospital and College of Medicine, Seoul, Republic of Korea; 11. Samsung Genome Institute, Samsung Medical Center, Seoul, Republic of Korea

Source PDF DOI Publisher page
146 days

Systemic immunosuppression limits NK cell therapy efficacy in pancreatic cancer

AuthorsChunbo He; Dezhen Wang; Tuo Hu; Daisy Gonzalez; Ravi Thakur; Damian P. Matysniak; Ryan J. King; Sai Sundeep Kollala; Spas Dimitrov Markov; Yuki Fujii; Gullanki Naga Venkata Charan Tej; Junzhang Zhao; Longyang Jin; Rebecca Oberley-Deegan; Surendra K. Shukla; Xin A. Zhang; Jacob E. Friedman; Pankaj K. Singh; Michael A. Hollingsworth; Marina Pasca di Magliano; Howard C. Crawford; Kamiya Mehla

Affiliations1. Department of Oncology Science, University of Oklahoma Health Campus, Oklahoma City, USA; 2. Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, USA; 3. Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, USA; 4. OU Health Stephenson Cancer Center, University of Oklahoma Health Campus, Oklahoma City, USA; 5. Department of Biochemistry and Physiology, University of Oklahoma Health Campus, Oklahoma City, USA; 6. Harold Hamm Diabetes Center, University of Oklahoma Health Campus, Oklahoma City, USA; 7. Department of Surgery, University of Michigan, Ann Arbor, USA; 8. Department of Pharmacology and Toxicology, Michigan State University, Lansing, USA; 9. Department of Surgery, Henry Ford Health System, Detroit, USA; 10. Department of Microbiology and Immunology, University of Oklahoma Health Campus, Oklahoma City, USA; 11. Department of Pathology, University of Oklahoma Health Campus, Oklahoma City, USA

Source PDF DOI Publisher page
100 days

IL-17–driven tumor cell–intrinsic inflammatory programming creates an immunotherapy-permissive microenvironment

AuthorsKosuke Murakami; Shiki Takamura; Chiho Miyagawa; Shiro Takamatsu; Yoko Kashima; Koji Nagaoka; Yukari Kobayashi; Yoshiyuki Hakata; Shigeki Kato; Sachiyo Tsuji-Kawahara; Ding Nan; Ronald Chandler; Satoru Takahashi; Masaaki Miyazawa; Kazuhiro Kakimi; Noriomi Matsumura

Affiliations1. Department of Obstetrics and Gynecology, Kindai University Faculty of Medicine, Sakai, Japan; 2. Laboratory for Immunological Memory, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan; 3. Department of Immunology, Kindai University Faculty of Medicine, Sakai, Japan; 4. Department of Arts and Sciences, Kindai University Faculty of Medicine, Sakai, Japan; 5. Department of Obstetrics, Gynecology and Reproductive Biology, College of Human Medicine, Michigan State University, East Lansing, USA; 6. Department of Anatomy and Embryology and Laboratory Animal Resource Center in Transborder Medical Research Center, Institute of Medicine, University of Tsukuba, Tsukuba, Japan

Source PDF DOI Publisher page
84 days

Deconstructing cancer in 3D: models, mechanisms, and personalized solutions

AuthorsZhao Huang; Xirui Duan; Jun Ji; Qu Cai; Ping Jin; Beiqin Yu; Jun Zhang

Affiliations1. West China Institute of Preventive and Medical Integration for Major Diseases, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China; 2. Department of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 3. Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 4. State Key Laboratory for Conservation and Utilization of Bio-Resources in Yunnan and Key Laboratory of Industrial Microbial Fermentation Engineering of Yunnan Province, School of Life Sciences, Yunnan University, Kunming, China; 5. Department of General Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 6. Shanghai Key Laboratory of Gastric Neoplasms, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Source PDF DOI Publisher page
123 days

Insight of immune checkpoint blockades in melanoma: mechanism and clinical translation

AuthorsQingyan Zhang; Chunhui Yuan; Lin Zhu; Shaobing Zheng; Yantao Xu; Xuanlin Che; Shiyu Xiao; Juan Liu; Hong Liu; Hui Li; Xiang Chen

Affiliations1. The Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China; 2. National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Central South University, Changsha, China; 3. National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China; 4. Hunan Key Laboratory of Skin Cancer and Psoriasis, Xiangya Hospital, Central South University, Changsha, China; 5. National Medical Metabolomics International Collaborative Research Center, Xiangya Hospital, Central South University, Changsha, China; 6. Furong Laboratory, Changsha, China; 7. Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, Changsha, China

Source PDF DOI Publisher page
36 days

Radionuclide‑drug conjugates in lung cancer: advances in precision therapy and clinical translation

AuthorsJunzhi Liu; Xiaoyu Zuo; Xue Yang; Xinyue Wang; Lu Gan; Jianxin Xue

Affiliations1. Division of Thoracic Tumour Multimodality Treatment, Cancer Center & State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China; 2. Department of Medical Oncology, Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China; 3. Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China; 4. Research Laboratory of Emergency Medicine, Department of Emergency Medicine, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, China; 5. Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu, China

Source PDF DOI Publisher page
85 days

Histone modifications across cancers: mechanisms, therapy and clinical translation

AuthorsPengde Lu; Yau-Tuen Chan; Chun-Fung Kwok; Qiucheng Li; Zhuofeng Jiang; Lin Xu; Zixin Feng; Hongchao Yuan; Jiaqi Zou; Yunqing Xun; Tung-Leong Fong; Chi-Ming Che; Ning Wang

Affiliations1. School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong S.A.R.,, P. R. China; 2. State Key Laboratory of Synthetic Chemistry, Department of Chemistry, The University of Hong Kong, Hong Kong, China; 3. Laboratory for Synthetic Chemistry and Chemical Biology Limited, Hong Kong Science Park, Hong Kong

Source PDF DOI Publisher page
202 days

Navigating luminal heterogeneity: etiology-based proteogenomic subtyping for targeted treatment strategies in breast cancer

AuthorsYa-Hsuan Chang; Yi-Ju Chen; Zhi-Jie Hong; Yi-Jing Hsiao; Kuen-Tyng Lin; Guo-Shiou Liao; Sheng-Fang Su; Ze-Shiang Lin; Huei-Wen Chen; Chia-Li Han; Eric Sheng-Wen Chen; Yin-Chen Hsu; Yan-Ming Chen; Hao Fang; Hao-Chin Yang; Yan-Si Chen; Chien-Yu Lin; Hsiang-En Hsu; Ching-Hung Lin; Pin-Lian Jiang; Pei-Shan Wu; Ching-Wen Chen; Chen-Ting Hung; Ethan Wu; Wei-Tzu Chiu; Fan-Ni Hsing; Tsai-Pei Liu; Chia-Yu Wang; Yu-Tai Wang; Chang-Wei Yeh; Ki-Hok Liao; Ana I Robles; Henry Rodriguez; Show-Ling Yang; Mien-Chie Hung; Yen-Shen Lu; Hsuan-Yu Chen; Sung-Liang Yu; Jyh-Cherng Yu; Yu-Ju Chen

Affiliations1. Institute of Molecular and Genomic Medicine, National Health Research Institutes, Miaoli, Taiwan; 2. Institute of Statistical Science, Academia Sinica, Taipei, Taiwan; 3. Center for Cancer Research, Kaohsiung Medical University, Kaohsiung, Taiwan; 4. Institute of Chemistry, Academia Sinica, Taipei, Taiwan; 5. Department of Surgery, Tri-Service General Hospital, National Defense Medical University, Taipei, Taiwan; 6. Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei, Taiwan; 7. Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan; 8. Graduate Institute of Toxicology, National Taiwan University College of Medicine, Taipei, Taiwan; 9. Master Program in Clinical Genomics and Proteomics, College of Pharmacy, Taipei Medical University, Taipei, Taiwan; 10. Department of Medical Oncology, Cancer Center Branch, National Taiwan University Hospital, Taipei, Taiwan; 11. Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan; 12. Department of Chemistry, National Taiwan University, Taipei, Taiwan; 13. National Center for High-performance Computing, National Institutes of Applied Research, Hsinchu, Taiwan; 14. Office of Cancer Clinical Proteomics Research, National Cancer Institute, National Institutes of Health, Rockville, USA; 15. Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan; 16. Graduate Institute of Biomedical Sciences, Cancer Biology and Precision Therapeutics Center, Center for Molecular Medicine, China Medical University, Taichung, Taiwan; 17. Ph.D. Program in Microbial Genomics, National Chung Hsing University, Taichung, Taiwan; 18. Department of Laboratory Medicine, National Taiwan University Hospital, Taipei, Taiwan

Source PDF DOI Publisher page
95 days

Multimodal sequencing identifies synergistic mechanisms driving resistance to neoadjuvant nivolumab treatment in hepatocellular carcinoma

AuthorsFanhong Zeng; Jiaxin Guo; Zheng Zeng; Vanilla Xin Zhang; Yu-Man Tsui; Po-Man Li; Abdullah Husain; Qingyang Zhang; Joyce Man-Fong Lee; Tan-To Cheung; Daniel Wai-Hung Ho; Irene Oi-Lin Ng

Affiliations1. Department of Pathology, The University of Hong Kong, Hong Kong, China; 2. State Key Laboratory of Liver Research, The University of Hong Kong, Hong Kong, China; 3. Department of Surgery, The University of Hong Kong, Hong Kong, China

Source PDF DOI Publisher page

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review96.4 days

Median77 days

Contact CrushSCI

Contact CrushSCI

Leave your contact details so we can discuss your manuscript, editing needs, and submission plan.

Selected service: Paper Editing Service

Or leave your contact details

WhatsApp, Telegram, WeChat, and email are all optional, but at least one is required. Once received, we will contact you as soon as possible.